Tiziana Life Sciences (Nasdaq: TLSA) announced that Chief Executive Officer Ivor Elrifi purchased 667,000 common shares on Nasdaq at $1.00 per share, increasing his total holding to 4,472,261 shares. The company highlights its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody being developed for immunomodulation.
According to Tiziana Life Sciences, 14 patients with non-active secondary progressive multiple sclerosis (na-SPMS) have been dosed with intranasal foralumab in an open-label expanded access program, with improvement or stability of disease observed within six months in all patients. Intranasal foralumab is also being evaluated in a Phase 2a randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in na-SPMS. The company states that foralumab is currently the only fully human anti-CD3 mAb in clinical development and that its intranasal delivery platform has shown a favorable safety profile and clinical responses to date.
Loading...
Loading translation...
Positive
CEO share purchase: Ivor Elrifi bought 667,000 shares at $1.00, raising his stake to 4,472,261 shares
Expanded access data: 14 na-SPMS patients showed improvement or disease stability within 6 months after intranasal foralumab
Ongoing Phase 2a trial: randomized, double-blind, placebo-controlled, dose-ranging study in na-SPMS underway for intranasal foralumab
Negative
None.
News Market Reaction – TLSA
-0.18%2.3x vol
6 alerts
-0.18%Session close to close
+8.9%Peak Tracked
-3.2%Trough Tracked
$139.99MMarket Cap
2.3xRel. Volume
In the Aug 4 session, TLSA declined 0.18%, reflecting a mild negative market reaction.
Argus tracked a peak move of +8.9% during that session.
Argus tracked a trough of -3.2% from its starting point during tracking.
Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Trading volume was elevated at 2.3x the daily average, suggesting increased selling activity.
Historical company-news reactions included -9.32% and +0.91%, showing varied responses. The CEO's pu...
Analysis
Historical company-news reactions included -9.32% and +0.91%, showing varied responses. The CEO's purchase adds insider-ownership context; the ongoing Phase 2a trial remains a separate clinical milestone, while short positioning was categorized as low.
Key Figures
Shares purchased:667,000 sharesPurchase price:$1.00 per shareTotal CEO holding:4,472,261 common shares+3 more
6 metrics
Shares purchased667,000 sharesCEO purchase on NASDAQ
Purchase price$1.00 per shareCEO share purchase
Total CEO holding4,472,261 common sharesFollowing the purchase
Expanded access patients14 patientsna-SPMS Expanded Access Program
Observed period6 monthsDisease improvement or stability in all patients
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Comparable company news produced mixed reactions, including declines after an insider purchase and after Phase 2a enrollment.
Key Terms
immunomodulation, anti-CD3 monoclonal antibody, expanded access, open-label, +2 more
6 terms
immunomodulationmedical
"a biotechnology company developing breakthrough immunomodulation therapies"
Immunomodulation is the intentional changing of the immune system’s activity—either ramping it up, calming it down, or redirecting it—to treat disease or prevent harmful reactions. Think of it like adjusting a thermostat for the body’s defenses: the goal is to achieve the right balance so patients heal without excessive inflammation or infection risk. For investors, immunomodulation matters because therapies in this area can address many diseases, carry regulatory and safety considerations, and often determine commercial potential and clinical risk.
anti-CD3 monoclonal antibodymedical
"intranasal foralumab, a fully human, anti-CD3 monoclonal antibody"
A lab-made antibody engineered to attach to CD3, a protein found on T cells, so it can change how those immune cells behave. Investors care because these drugs can act like a targeted brake on an overactive immune system—useful for autoimmune disease, transplant rejection or as part of cancer therapies—but they also carry clinical trial, safety and regulatory risks that determine commercial success.
Access that lets patients use an experimental drug or medical device outside of a formal clinical trial when no approved options are available. Think of it like allowing someone to test-drive a prototype car because they have no other transportation; for investors, expanded access can affect short-term demand, provide additional safety or usage information, and carry reputational or regulatory risks that may influence a company’s prospects and potential future sales.
open-labelmedical
"have been dosed in an open-label intermediate sized Expanded Access"
Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.
double-blindmedical
"a Phase 2a, randomized, double-blind, placebo-controlled"
A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.
A dose-ranging study is a clinical trial that tests multiple amounts of a drug to find what dose works best and is safest, much like trying different spice levels in a recipe to get the right balance. For investors, results clarify whether a medicine is effective at practical doses, how likely it is to win regulatory approval, what side effects to expect, and how the treatment might be priced and used in the market.
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Chief Executive Officer, Ivor Elrifi has increased his holdings with the purchase of 667,000 of the Company’s common shares on NASDAQ at $1.00 per share, bringing his total holding to 4,472,261 common shares.
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients.In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.
For further inquiries:
Tiziana Life Sciences Ltd Paul Spencer, Business Development, and Investor Relations +44 (0) 207 495 2379 email: info@tizianalifesciences.com
What insider share purchase did Tiziana Life Sciences (NASDAQ: TLSA) announce on August 4, 2026?
Tiziana Life Sciences reported that CEO Ivor Elrifi bought 667,000 TLSA common shares at $1.00 per share. According to Tiziana Life Sciences, this transaction increased his total holding to 4,472,261 shares, signaling additional personal exposure to the company’s equity.
How many TLSA shares does CEO Ivor Elrifi own after the August 2026 purchase?
After purchasing 667,000 shares at $1.00 each, CEO Ivor Elrifi holds 4,472,261 TLSA common shares. According to Tiziana Life Sciences, this updated total reflects his increased ownership following the Nasdaq market transaction disclosed on August 4, 2026.
What is intranasal foralumab being developed by Tiziana Life Sciences (TLSA)?
Intranasal foralumab is a fully human anti-CD3 monoclonal antibody designed for immunomodulation via nasal delivery. According to Tiziana Life Sciences, it stimulates T regulatory cells and is being developed as a novel treatment approach for neuroinflammatory and neurodegenerative diseases, including non-active secondary progressive multiple sclerosis.
What clinical data has Tiziana Life Sciences reported for foralumab in non-active secondary progressive multiple sclerosis?
Tiziana Life Sciences reports 14 na-SPMS patients treated with intranasal foralumab in an open-label expanded access program. According to Tiziana Life Sciences, all showed either improvement or disease stability within six months, providing initial clinical observations supporting further controlled studies.
What ongoing clinical trials involve intranasal foralumab for TLSA as of 2026?
Intranasal foralumab is in a Phase 2a randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in na-SPMS. According to Tiziana Life Sciences, this study builds on data from an intermediate-sized expanded access program that previously dosed 14 patients with non-active secondary progressive multiple sclerosis.
Why does Tiziana Life Sciences describe foralumab as unique among anti-CD3 antibodies?
Tiziana Life Sciences states that foralumab is the only fully human anti-CD3 monoclonal antibody currently in clinical development. According to Tiziana Life Sciences, its intranasal administration and immunomodulatory mechanism may offer a differentiated treatment option for neuroinflammatory and neurodegenerative conditions.
